Biotech News

SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

SCYNEXIS (SCYX)SCYNEXISCompany update

SCYX (SCYX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is scyx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

SCYNEXIS

Metabolic Kidney-Disease Lead Program SCYNEXIS is developing SCY-770, an orally administered, selective direct activator of AMPK acquired as PXL-770. The program is being advanced for autosomal dominant polycystic kidney disease, where AMPK activation may address multiple drivers of disease progression. Antifungal Franchise SCY-247 is...

Recent company news

Stock data

Close
5.20 USD
Market cap
50.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States